Ian Sanne to South Africa
This is a "connection" page, showing publications Ian Sanne has written about South Africa.
Connection Strength
2,609
-
Voluntary medical male circumcision in selected provinces in South Africa: Outcomes from a programmatic setting. PLoS One. 2022; 17(9):e0270545.
Score: 0,082
-
Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste. S Afr Med J. 2022 02 01; 112(2):13501.
Score: 0,078
-
Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open. 2017 06 10; 7(6):e015620.
Score: 0,057
-
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One. 2016; 11(11):e0164974.
Score: 0,054
-
Managing Human Tissue Transfer Across National Boundaries - An Approach from an Institution in South Africa. Dev World Bioeth. 2016 Apr; 16(1):29-35.
Score: 0,048
-
Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy. Int J Tuberc Lung Dis. 2014 Nov; 18(11):1340-6.
Score: 0,047
-
Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
Score: 0,047
-
CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on antiretroviral therapy. J Int AIDS Soc. 2014; 17:19139.
Score: 0,047
-
A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014 Jan; 15(1):3-12.
Score: 0,044
-
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
Score: 0,043
-
Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013 Mar; 17(3):368-72.
Score: 0,042
-
Tenofovir use and pregnancy among women initiating HAART. AIDS. 2012 Nov 28; 26(18):2393-7.
Score: 0,041
-
Treatment outcomes after 7 years of public-sector HIV treatment. AIDS. 2012 Sep 10; 26(14):1823-8.
Score: 0,041
-
Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol. 2013 Apr; 42(2):430-9.
Score: 0,040
-
Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012 Mar 12; 15(1):13.
Score: 0,039
-
Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar; 113(3):362-72.
Score: 0,039
-
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
Score: 0,037
-
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
Score: 0,036
-
Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One. 2010 Sep 14; 5(9):e12731.
Score: 0,036
-
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
Score: 0,035
-
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
Score: 0,034
-
Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010 Apr; 15(4):405-13.
Score: 0,034
-
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
Score: 0,032
-
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol. 2009 Jan-Feb; 53(1):10-7.
Score: 0,032
-
The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008 Aug; 13(8):1005-15.
Score: 0,031
-
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008 Jul 01; 48(3):334-44.
Score: 0,031
-
Trends in COVID-19 admissions and deaths among people living with HIV in South Africa: analysis of national surveillance data. Lancet HIV. 2024 Feb; 11(2):e96-e105.
Score: 0,022
-
Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa. Vaccine. 2024 Feb 27; 42(6):1195-1199.
Score: 0,022
-
The cardiovascular consequences of HIV and antiretroviral therapy. Cardiovasc J S Afr. 2003 Sep-Oct; 14(5):225-9.
Score: 0,022
-
Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. Clin Infect Dis. 2023 04 17; 76(8):1468-1475.
Score: 0,021
-
Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts. Sci Rep. 2022 07 26; 12(1):12715.
Score: 0,020
-
Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Med. 2022 06; 19(6):e1004024.
Score: 0,020
-
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022 03 19; 399(10330):1141-1153.
Score: 0,020
-
Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One. 2022; 17(2):e0262442.
Score: 0,020
-
Sisonke phase 3B open-label study: Lessons learnt for national and global vaccination scale-up during epidemics. S Afr Med J. 2021 12 24; 112(2b):13486.
Score: 0,019
-
Deciding when to institute terminal palliative care for AIDS patients--an evidence-based approach. S Afr Med J. 2001 Jul; 91(7):559-60.
Score: 0,019
-
Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa. PLoS One. 2021; 16(6):e0252317.
Score: 0,019
-
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. N Engl J Med. 2021 08 05; 385(6):570-571.
Score: 0,019
-
The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity. Clin Infect Dis. 2021 05 04; 72(9):1642-1644.
Score: 0,019
-
Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa. Glob Health Action. 2021 01 01; 14(1):1865625.
Score: 0,018
-
The Scientists' Collective 10-point proposal for equitable and timeous access to COVID-19 vaccine in South Africa. S Afr Med J. 2020 12 14; 0(0):13163.
Score: 0,018
-
The Scientists' Collective 10-point proposal for equitable and timeous access to COVID-19 vaccine in South Africa. S Afr Med J. 2020 12 14; 111(2):89-94.
Score: 0,018
-
The role of serological testing in the SARS-CoV-2 outbreak. S Afr Med J. 2020 07 17; 110(9):842-845.
Score: 0,018
-
Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa. BMC Infect Dis. 2020 May 04; 20(1):320.
Score: 0,017
-
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. AIDS. 2020 04 01; 34(5):681-686.
Score: 0,017
-
Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
Score: 0,017
-
Treatment outcomes among HIV-positive orphaned and non-orphaned children on antiretroviral therapy in Johannesburg, South Africa. S Afr Med J. 2019 Aug 28; 109(9):679-685.
Score: 0,017
-
HIV incidence, pregnancy, and implementation outcomes from the Sakh'umndeni safer conception project in South Africa: a prospective cohort study. Lancet HIV. 2019 07; 6(7):e438-e446.
Score: 0,016
-
"Even if you're HIV-positive there's life after if you take your medication": experiences of people on long-term ART in South Africa: a short report. AIDS Care. 2019 08; 31(8):973-978.
Score: 0,016
-
Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
Score: 0,016
-
Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLoS One. 2018; 13(10):e0204020.
Score: 0,016
-
Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS One. 2018; 13(8):e0201955.
Score: 0,015
-
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018 06 18; 67(1):34-41.
Score: 0,015
-
Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Trop Med Int Health. 2018 06; 23(6):650-660.
Score: 0,015
-
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
Score: 0,015
-
Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
Score: 0,015
-
Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
Score: 0,014
-
Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS. 2017 Jul 17; 31(11):1611-1619.
Score: 0,014
-
Client uptake of safer conception strategies: implementation outcomes from the Sakh'umndeni Safer Conception Clinic in South Africa. J Int AIDS Soc. 2017 03 08; 20(Suppl 1):21291.
Score: 0,014
-
Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open. 2017 01 24; 7(1):e013908.
Score: 0,014
-
Evaluation of the Tsima community mobilization intervention to improve engagement in HIV testing and care in South Africa: study protocol for a cluster randomized trial. Implement Sci. 2017 Jan 17; 12(1):9.
Score: 0,014
-
Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res. 2017 Jan 17; 17(1):41.
Score: 0,014
-
Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
Score: 0,014
-
Treatment Outcomes and Costs of Providing Antiretroviral Therapy at a Primary Health Clinic versus a Hospital-Based HIV Clinic in South Africa. PLoS One. 2016; 11(12):e0168118.
Score: 0,014
-
Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
Score: 0,014
-
Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017 02; 22(2):221-231.
Score: 0,014
-
Prevalence of latent tuberculosis infection and predictive factors in an urban informal settlement in Johannesburg, South Africa: a cross-sectional study. BMC Infect Dis. 2016 11 08; 16(1):661.
Score: 0,014
-
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017 01; 17(1):39-49.
Score: 0,014
-
Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. J Infect Dis. 2016 Dec 15; 214(12):1826-1830.
Score: 0,014
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
Score: 0,014
-
Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
Score: 0,013
-
Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. Int J Tuberc Lung Dis. 2016 08; 20(8):1040-5.
Score: 0,013
-
Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med. 2016 May; 13(5):e1002015.
Score: 0,013
-
The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa. PLoS One. 2016; 11(2):e0148546.
Score: 0,013
-
Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis. 2016 May 01; 62(9):1081-8.
Score: 0,013
-
Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
Score: 0,013
-
Brief Report: Does Most Mortality in Patients on ART Occur in Care or After Lost to Follow-Up? Evidence From the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr. 2015 Nov 01; 70(3):323-8.
Score: 0,013
-
"I don't know if this is right … but this is what I'm offering": healthcare provider knowledge, practice, and attitudes towards safer conception for HIV-affected couples in the context of Southern African guidelines. AIDS Care. 2016; 28(3):390-6.
Score: 0,013
-
Acceptability and preferences for safer conception HIV prevention strategies: a qualitative study. Int J STD AIDS. 2016 10; 27(11):984-92.
Score: 0,013
-
Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa. Pan Afr Med J. 2015; 22:4.
Score: 0,013
-
The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
Score: 0,012
-
The impact of Xpert(®) MTB/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015 Apr; 19(4):392-8.
Score: 0,012
-
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3.
Score: 0,012
-
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17:19065.
Score: 0,012
-
High uptake of systematic HIV counseling and testing and TB symptom screening at a primary care clinic in South Africa. PLoS One. 2014; 9(9):e105428.
Score: 0,012
-
Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa. Trop Med Int Health. 2014 Dec; 19(12):1411-9.
Score: 0,012
-
Implementation of a safer conception service for HIV-affected couples in South Africa. AIDS. 2014 Jul; 28 Suppl 3:S277-85.
Score: 0,012
-
Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
Score: 0,012
-
A home tracing program for contacts of people with tuberculosis or HIV and patients lost to care. Int J Tuberc Lung Dis. 2014 May; 18(5):534-40.
Score: 0,011
-
Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
Score: 0,011
-
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
Score: 0,011
-
Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014; 17:18651.
Score: 0,011
-
Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925.
Score: 0,011
-
Effect of antiretroviral therapy on patients' economic well being: five-year follow-up. AIDS. 2014 Jan 28; 28(3):417-24.
Score: 0,011
-
Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900.
Score: 0,011
-
Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
Score: 0,011
-
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
Score: 0,011
-
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
Score: 0,011
-
HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):839-44.
Score: 0,011
-
Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013 Feb 20; 27(4):645-50.
Score: 0,011
-
The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. 2013 May; 18(5):619-31.
Score: 0,011
-
Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health. 2013 Apr; 18(4):451-60.
Score: 0,010
-
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e39-46.
Score: 0,010
-
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e55-7.
Score: 0,010
-
Linkage to care and treatment for TB and HIV among people newly diagnosed with TB or HIV-associated TB at a large, inner city South African hospital. PLoS One. 2013; 8(1):e49140.
Score: 0,010
-
Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J. 2013 Jan 14; 103(2):101-6.
Score: 0,010
-
Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health. 2013 Jan; 18(1):109-16.
Score: 0,010
-
The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
Score: 0,010
-
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
Score: 0,010
-
Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
Score: 0,010
-
Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health. 2012 Sep; 17(9):1142-51.
Score: 0,010
-
The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012; 7(5):e36966.
Score: 0,010
-
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
Score: 0,010
-
Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
Score: 0,010
-
Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23; 25(16):2027-36.
Score: 0,010
-
Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):57-65.
Score: 0,010
-
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
Score: 0,010
-
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011 Aug 24; 25(13):1603-9.
Score: 0,009
-
Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
Score: 0,009
-
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
Score: 0,009
-
Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011 Jul; 8(7):e1001055.
Score: 0,009
-
The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011 May 15; 14:24.
Score: 0,009
-
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
Score: 0,009
-
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc. 2010 Dec 07; 13:49.
Score: 0,009
-
Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc. 2010 Sep 07; 13:33.
Score: 0,009
-
Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
Score: 0,009
-
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
Score: 0,009
-
Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010 Jun; 15 Suppl 1:43-7.
Score: 0,009
-
Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ. 2010 Sep 01; 88(9):675-80.
Score: 0,009
-
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
Score: 0,009
-
The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010 Mar 27; 24(6):915-9.
Score: 0,009
-
Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control. 2010 Mar; 21(3):433-43.
Score: 0,008
-
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
Score: 0,008
-
Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009 Jul; 13(4):488-92.
Score: 0,008
-
Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug; 7(4):200-7.
Score: 0,008
-
Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS. 2008 Jul; 22 Suppl 1:S131-9.
Score: 0,008
-
The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J. 2008 Jul; 98(7):541-4.
Score: 0,008
-
Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S40-51.
Score: 0,007
-
CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
Score: 0,007
-
Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr. 2007 Sep 01; 46(1):91-100.
Score: 0,007
-
Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007 Jul; 97(7):524-9.
Score: 0,007
-
High tuberculosis and HIV coinfection rate, Johannesburg. Emerg Infect Dis. 2007 May; 13(5):795-6.
Score: 0,007
-
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15; 43(6):783-6.
Score: 0,007